Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests better embryo transfer prep for women with adenomyosis

NCT ID NCT06239376

First seen Mar 27, 2026 · Last updated Jun 22, 2026 · Updated 10 times

Summary

This study tests whether a two-month hormone pretreatment (GnRH agonist plus letrozole) before standard frozen embryo transfer preparation leads to more live births than standard preparation alone in women with adenomyosis. About 222 women aged 18-42 will be randomly assigned to one of the two groups. The goal is to find a more effective way to help these women have a baby.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOMYOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • My Duc Hospital

    RECRUITING

    Ho Chi Minh City, Ho Chi Minh City, 70000, Vietnam

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GnRH agonist (Diphereline) and letrozole (Femara) followed by estradiol valerate and progesterone

What this could lead to

If successful, this could identify a better way to prepare the uterus for embryo transfer in women with adenomyosis, potentially increasing the chance of a live birth.

What could go wrong

This is a relatively small, early-phase trial (222 participants) comparing two existing protocols, so results may not be definitive or widely applicable. Side effects from the hormone treatments are possible.

Conditions

The condition(s) this trial relates to.

adenomyosis ventricular fibrillation, paroxysmal familial, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.